Cargando…
Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors
PURPOSE: We explored the clinical and genomic characteristics of hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (MBC) after progression on cyclin-dependent kinase 4 and 6 inhibitors (CDK4 and 6i) ± endocrine therapy (ET) to understand potential resistance mechanisms...
Autores principales: | Rao, Xi, Chen, Yongmei, Beyrer, Julie, Nash Smyth, Emily, Morato Guimaraes, Claudia, Litchfield, Lacey M., Bowman, Lee, Lawrence, Garreth W., Aggarwal, Amit, Andre, Fabrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472108/ https://www.ncbi.nlm.nih.gov/pubmed/37289194 http://dx.doi.org/10.1158/1078-0432.CCR-22-3843 |
Ejemplares similares
-
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023) -
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022) -
Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
por: Bleach, Rachel, et al.
Publicado: (2021) -
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
por: Woyach, Jennifer A., et al.
Publicado: (2023) -
Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands
por: Kwon, Daniel, et al.
Publicado: (2022)